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The surge in the consumption of food products containing herbal aphrodisiacs has 
driven their widespread adulteration. A rapid screening strategy is, therefore, 
warranted to curb this problem. This study established an enzyme inhibition assay to 
screen phosphodiesterase 5 (PDE5) inhibitors as adulterants in selected food 
products. Fluorescein-labelled cyclic-3’,5’-guanosine monophosphate was utilised as 
substrates for the PDE5A1 enzyme, aided by the presence of nanoparticle phosphate-
binding beads on their fluorescence polarisation. The sample preparation was 
optimised to improve the enzyme inhibition efficiency and applied to calculate the 
threshold values of six blank food matrices. The assay was validated using sildenafil, 
producing an IC50 of 4.2 nM. The applicability of the assay procedure was 
demonstrated by screening 55 distinct food samples. The results were subsequently 
verified using confirmatory liquid chromatography-high-resolution mass spectrometry 
(LC-HRMS) analysis. Altogether, 49 samples inhibited the PDE5 enzyme above the 
threshold values (75.7%–105.5%) and were registered as potentially adulterated 
samples. The remaining six samples were marked as non-adulterated with percentage 
inhibition below the threshold values (-3.3%–18.2%). The LC-HRMS analysis agreed 
with the assay results for all food products except for the instant coffee premix (ICP) 
samples. False-positive results were obtained for the ICP samples at 32% (8/25), due 
to possible PDE5 inhibition by caffeine. Contrarily, all other food samples were found 
to produce 0% (0/30) false-positive or false-negative results. The broad-based assay, 
established via a simple mix-incubate-read format, exhibited promising potential for 
high-throughput screening of PDE5 inhibitors in various food products, except those 
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INTRODUCTION 
The immense success of sildenafil, vardenafil, and tadalafil has since led to the 
massive influx of adulterated herbal remedies into the market, typically labelled to 
contain herbal aphrodisiacs with claims to enhance male sexual performance. These 
adulterated products are frequently marketed as herbal medicines and dietary 
supplements; and advertised as all-natural, without any side-effects1-3. However, in 
recent years, the trend has shifted towards food products as they are not heavily 
regulated compared to those in pharmaceutical dosage forms4. These food products 
can be easily purchased through drugstores, supermarkets, convenience stores, 
herbal shops, restaurants, electronic commerce platforms, and black markets5. Most 
of them, unfortunately, were found to be adulterated with phosphodiesterase 5 (PDE5) 
inhibitors and their analogues6,7. The widespread adulteration has sparked an 
elevated food safety and public health concerns, as consumers are often unaware of 
the risks associated with the consumption of such products8. 
 
PDE5 inhibitors are generally synthesised to mimic the structure of the purine ring of 
cyclic-3’,5’-guanosine monophosphate (cGMP)9. Due to the structural similarities, 
these drugs competitively bind to the catalytic domain of PDE5 enzyme, subsequently 
inhibiting the cGMP degradation; thus, enhancing the effects of nitric oxide. The series 
of events sustain cGMP levels and prolong penile erection10. PDE5 enzyme, on the 
contrary, acts through a negative feedback control mechanism in the corpus 
cavernosum. It degrades cGMP to the inactive 5'-guanosine monophosphate (GMP), 
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resulting in penile detumescence11,12. Based on the penile erection mechanism, the 
differences between cGMP (substrate) and GMP (product) levels may indicate the 
presence or absence of PDE5 inhibitors. 
 
At present, several analytical methods have been utilised to determine PDE5 inhibitors 
in various matrices13-16. More commonly, liquid chromatography (LC) coupled with 
tandem mass spectrometry (MS/MS) has proven to be invaluable in the analysis of 
PDE5 inhibitors17,18. However, LC-MS/MS, in general, demands higher operational 
and maintenance costs with limited sample throughput. It also requires experienced 
users to operate the analytical instrument and interpret the MS data19. Therefore, a 
rapid, simple, and cheap screening test is warranted to discriminate adulterated from 
the non-adulterated food products, particularly those with PDE5 inhibitors and their 
analogues. 
 
Only a few rapid screening tests have been proposed to discriminate PDE5 inhibitors 
in adulterated or counterfeit products based on colour changes20 and 
immunochromatographic assay21-23. However, both of these techniques are targeted 
for a distinct PDE5 inhibitor or a group of PDE5 inhibitors, making them limited for 
broad-based screening. A study has recently proposed a broad-based screening of 
PDE5 inhibitors in herbal dietary supplements via the PDE5 inhibition assay24. The 
assay utilised fluorescence intensity measurements of tetramethyl rhodamine-labelled 
cGMP in the presence of zirconyl chloride octahydrate as a quenching agent. This 
study, however, was not validated using real samples and the need to measure the 




Herein, a broad-based enzyme inhibition assay was established via a simple mix-
incubate-read format to rapidly screen PDE5 inhibitors, found as adulterants in 
selected food products. A PDE5-specific cGMP fused with a fluorescein fluorophore 
via a 9-atom spacer moiety, known as FAM-cGMP, was utilised as substrates for the 
human recombinant PDE5A1 enzyme. The substrate depletion and the product 
formation from the PDE5 enzyme activity were measured using their molecular 
movements and rotations, aided by the presence of nanoparticle phosphate-binding 
beads on their fluorescence polarisation (FP). The assay was optimised and validated 
to improve the enzyme inhibition efficiency and to certify the robustness of the assay 
performance, respectively. Altogether, 55 distinct food samples were submitted to the 
PDE5 inhibition assay, and the results were subsequently verified using confirmatory 
liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis. To 
the best of our knowledge, this is the first study utilising the FP technique to rapidly 
screen PDE5 inhibitors as adulterants in food products via PDE5 inhibition assay. This 
paper also highlighted the advantages as well as the shortcomings encountered in 
detecting the adulterated food products. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
The PDE5A1 assay kit (Catalogue No. 60351) was purchased from BPS Bioscience 
Inc. (San Diego, CA, United States). It comprised the following: human recombinant 
PDE5A1 enzyme (PDE5 enzyme) 0.36 mg/mL (Catalogue No. 60050), fluorescein-
labelled cGMP substrate (FAM-cGMP) 20 µM (Catalogue No. 60201), 
phosphodiesterase (PDE) assay buffer (Catalogue No. 60393), PDE binding agent 
(Catalogue No. 60390), PDE binding agent diluent for cGMP (Catalogue No. 60392), 
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and Greiner 384-well microtiter plate (black, low binding, flat bottom) with a clear lid. 
The vendor for sildenafil certified reference material was TLC Pharmaceutical 
Standards Ltd. (Aurora, Ontario, Canada); while Sigma Aldrich Pty Ltd. (Castle Hill, 
NSW, Australia) supplied the dimethyl sulfoxide (DMSO) of analytical grade. 
 
2.2. Standard solution preparation 
The stock solution of sildenafil was prepared at 1 mM in DMSO and stored at 4°C in 
the dark. To validate the PDE5 inhibition assay, different concentration solutions of 
sildenafil ranging from 0.01–100 μM were prepared from the stock solution, serially 
diluted in DMSO. Each of these solutions was further diluted at 10-fold in PDE assay 
buffer before being submitted to the assay, producing a final 100-fold dilution of 
sildenafil in each microtiter plate well. 
 
2.3. Sample collection and storage 
A total of 50 distinct food samples were obtained from Malaysia (48 samples) and 
Australia (2 samples), in the form of instant coffee premix (ICP, 25 samples), 
powdered drink mix (PDM, 16 samples), honey (HNY, 4 samples), jelly (JLY, 2 
samples), hard candy (HCD, 2 samples), and chewing gum (CWG, 1 sample). These 
suspected adulterated food products were selected based on the brand names, label 
claims, images, herbal ingredients, or advertising materials with connotations of male 
sexual performance. The Pharmacy Enforcement Division, Ministry of Health 
Malaysia, kindly donated two-thirds of these samples, which were confiscated by the 
pharmacy enforcement officers at the international airport (5 samples) and 
international seaport (10 samples), as well as from routine market surveillance 
activities (19 samples). The rest of the samples were purchased from various 
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electronic commerce platforms established in Malaysia (14 samples) and Australia (2 
samples). The samples were kept in separate plastic zip-lock bags and stored in an 
airtight container in the dark. Blank matrices of each food products, free from any 
analyte of interests, were sourced from a local supermarket in Australia and used to 
establish the threshold value of PDE5 inhibition for adulterated food products. The 
compositions of each of the blank food matrices are outlined in Table S1 (supporting 
information) based on the products’ label. Due to the small sample size of PDM, HNY, 
JLY, HCD, and CWG, their blank matrices were included as additional samples 
providing a total of 55 food samples. 
 
2.4. Sample preparation 
The initial weight of each sample was recorded based on the recommended daily 
intake on its label. These samples were divided into group A (ICP, PDM, and HNY; 
with average recommended daily intake of >5 mg) and group B (JLY, HCD, and CWG; 
with average recommended daily intake of <5 mg). The samples in group A were taken 
directly from their sachets, while samples from group B were initially homogenised 
with mortar and pestle. For PDE5 inhibition assay, 50 mg of group A samples or 10 
mg of group B samples were weighed in a polypropylene tube and then extracted with 
5 mL of DMSO via 1-min vortex mixing, 20-min sonication and 5-min centrifugation at 
2500 × g, successively. Using a 0.22 mm PTFE syringe filter, the upper layer was 
filtered and diluted for enzyme inhibition assay with the PDE assay buffer at 10-fold 
dilution, yielding a final 100-fold dilution of samples in each microtiter plate well. The 





2.5. PDE5 inhibition assay protocol 
Table 1 outlines the schematic three-step protocol of the PDE5 inhibition assay. The 
PDE5 inhibition assay established in this study was adapted and modified according 
to the manufacturer’s instruction25. Initially, the stock solutions of the PDE5 enzyme 
and FAM-cGMP substrate were respectively diluted with PDE assay buffer to produce 
10 pg/μL and 200 nM working solutions. The reagents, PDE5 inhibitors, and samples 
solutions were pipetted into each well of the microtiter plate according to step 1. 
Subsequently, each assay; comprised of blank, substrate control, positive control, and 
sample analysis; was covered with the microtiter plate’s lid and incubated at room 
temperature for an hour. Step 2 involved the addition of 50 µL PDE binding agent into 
each well, initially diluted 100-fold with PDE binding agent diluent. The mixtures were 
covered with the microtiter plate’s lid and incubated at room temperature for 20 min 
with slow shaking before submitting it to FP measurements via Tecan Infinite M1000 
Pro plate reader (Tecan Group Limited, Switzerland) in step 3. The wavelength of the 
FP was set within 5 nm bandwidth for excitation at 470 nm, and within 20 nm 
bandwidth for emission at 528 nm. The gain and Z-position values were automatically 
calculated from the positive control well. The calibration was performed from the 
substrate control well by correcting the G-factor to achieve a fixed value of 22 mP. The 
readings were captured at 10 flashes with a settling time of 500 ms. All assays were 
performed in triplicate wells, and the results obtained were automatically subtracted 
with the blank well readings. The well-to-well precision was expressed as a percentage 






2.6. LC-HRMS analysis 
The confirmatory LC-HRMS analysis was employed to verify the findings of the PDE5 
inhibition assay using an Agilent Technologies (Santa Clara, CA, USA) 1290 Infinity II 
LC system coupled to an Agilent Technologies 6510 quadrupole time-of-flight mass 
spectrometry (QTOF-MS) according to the previous literature26-28. 
 
2.7. Data analysis 
The Tecan i-control software version 1.11.1.0 automatically calculated all the FP 
values. The differences between the parallel and the perpendicular emission light 
intensities, normalised by the total fluorescence emission intensity of the excitation 
light plane, generated the absolute FP value based on Eq. 1 and represented in 
millipolarisation (mP) unit29. 
𝐹𝑃 (𝑚𝑃) =  
I∥ −  I⊥
I∥ +  I⊥
 × 1000 Eq. 1 
where I∥ is the parallel emission light intensities; I⊥ is the perpendicular 
emission light intensities. 
 
 
The substrate control and the positive control theoretically produced 0% and 100% 
enzyme-substrate activity, respectively. Therefore, the percentage of PDE5 enzyme 
activity of a given sample or PDE5 inhibitor can be determined using Eq. 2. 
% 𝑜𝑓 𝑃𝐷𝐸5 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝐹𝑃𝑆𝑃𝐿 − 𝐹𝑃𝑆𝑈𝐵
𝐹𝑃𝑃𝑂𝑆 − 𝐹𝑃𝑆𝑈𝐵
 × 100% Eq. 2 
where FPSPL is fluorescence polarisation of a sample; FPSUB is fluorescence 






The percentage of PDE5 inhibition was calculated based on Eq. 3.  
% 𝑜𝑓 𝑃𝐷𝐸5 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − % 𝑜𝑓 𝑃𝐷𝐸5 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 Eq. 3 
 
The threshold value of PDE5 inhibition (Tinhibition) was calculated via the 99.7% normal 
distribution rule for each food products using Eq. 430,31. All of these values were 
calculated using Microsoft (Redmond, WA, USA) Excel 2016 Microsoft Office. 
𝑇𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  𝜇 + 3𝜎 Eq. 4 
where µ is the average % of PDE5 inhibition; σ is the standard deviation.  
 
The calculated percentages of PDE5 activity of sildenafil versus their concentrations 
were plotted into a concentration-response inhibition curve using Prism GraphPad 
software version 8.0.1 by GraphPad Software Inc. (San Diego, CA, United States), 
and then fitted into a non-linear regression model of log10 (inhibitor) versus response 
(variable slope, four parameters) in Eq. 5. The non-linear regression data 
transformation automatically generated the half-maximal inhibitory concentration 
(IC50) of sildenafil via the symmetrical sigmoidal curve model. 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(𝐿𝑜𝑔 𝐼𝐶50−𝑋)×𝐻𝑖𝑙𝑙 𝑆𝑙𝑜𝑝𝑒 
 Eq. 5 
where X is log10 [inhibitor] concentration; Y is % of PDE5 activity; Top is 









3. RESULTS AND DISCUSSION 
3.1. PDE5 inhibition assay scheme 
The high-throughput screening of PDE5 inhibitors in food products was established 
via the PDE5 inhibition assay. This bioactivity-based assay utilises an FP technique 
to screen PDE5 inhibitors such as sildenafil (Fig. 1A), by competing with FAM-cGMP 
to bind to the catalytic domain of PDE5 enzyme (Fig. 1B)9,11. Therefore, the assay 
provides a broad-based screening for multiple PDE5 inhibitors that is non-targeted for 
a distinct inhibitor or a group of inhibitors, which is helpful to tackle the proliferation of 
novel analogues, deliberately added into various food products. The assay utilises a 
PDE5-specific cGMP substrate fused with a fluorescein fluorophore via a 9-atom 
spacer moiety, known as FAM-cGMP (Fig. 1C). The cGMP plays a pivotal role in the 
mechanism of penile erection32. 
 
Fig. 2 presents the schematic illustration of the PDE5 inhibition assay using FP 
technique. The enzymatic reaction initiation by the PDE5 enzyme, hydrolysed the 
phosphodiester bond of FAM-cGMP (substrate) to produce the inactive FAM-GMP 
(product) over a length of time. Once the incubation period ended, a PDE binding 
agent composed of nanoparticle beads is added to the assay to selectively bind the 
phosphate group of the FAM-GMP, consequently increasing its size. As a result, the 
FAM-cGMP and the FAM-GMP are distinguishable using FP based on the differences 
in their molecular weight. The low molecular weight FAM-cGMP (small, unbound 
molecule) produces a rapid rotational movement when excited with polarised light, 
generating low FP readings via depolarised light emission. Contrarily, the high 
molecular weight FAM-GMP-bead complex (large, bound molecule) rotates slowly 
during excitation with polarised light, continuing its polarisation with high FP readings. 
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The adulteration of food products with PDE5 inhibitors can initially be suspected with 
low FP readings as their presence blocks the hydrolysis of FAM-cGMP to FAM-GMP. 
However, to undoubtedly discriminate adulterated from the non-adulterated food 
products, these FP readings are transformed into the percentage of PDE5 inhibition 
and then compared with the threshold values obtained for each blank food matrix. The 
established PDE5 inhibition assay via FP is based on a simple and automation-
friendly33 mix-incubate-read format to screen PDE5 inhibitors in food products. 
Therefore, the demand for multiple readings over a length of time to monitor the 
enzymatic reaction progress was eliminated, and thus fitted the assay for high-
throughput screening. 
 
3.2. Optimisation of sample preparation 
The quality of sample preparation is one of the pivotal factors in determining the 
success of an enzyme inhibition assay. Therefore, it is crucial to prepare the samples 
into a form that is compatible with the assay procedure. Food products that claimed to 
enhance male sexual performance may contain an array of PDE5 inhibitors with 
diverse chemical structures, often exhibiting different inhibitory effects depending on 
their concentrations. Besides, the information on the potency of almost all unapproved 
PDE5 inhibitor analogues remains scarce in the literature. Due to these ambiguities, 
the sample preparation procedure in this study was established based on sildenafil as 
a representative adulterant, within its recommended dose of 25–100 mg. 
 
The weight of different types of food products was initially assessed to determine the 
appropriate ratio of the sample and the adulterant (sildenafil) to produce optimal PDE5 
inhibition. The sample weight was then fixed based on these findings for a specific 
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group of food products as detailed in Section 2.4. Ideally, the selected sample weight 
should produce an acceptable sensitivity via inhibitory potency at the lowest level of 
adulterant, avoiding false-negative results, while, at the same time, preventing 
oversaturation of the enzyme at the highest adulterant's level. The detailed calculation 
for samples in group A (ICP, PDM, and HNY) and group B (JLY, HCD, and CWG) are 
provided in Excel Spreadsheets S1 and S2 (supporting information), respectively, 
based on the minimum and maximum dose of sildenafil. The effect of interferences, 
particularly from the matrix components of the food products, should also be 
ascertained to ensure reliable assay performance; thus, avoiding false-positive 
results. 
 
A threshold value of PDE5 inhibition was established for each blank matrices of the 
food products to discriminate adulterated from the non-adulterated samples. The 
threshold value used in this study represents the percentage of PDE5 inhibition at 
which the likelihood of obtaining a false-positive result from a blank, non-adulterated 
food product is <0.3% using the 99.7% normal distribution rule30,31. Adulterated food 
samples are qualified by their average PDE5 inhibition above the threshold value, 
while those below the threshold are categorised as non-adulterated samples. Each of 
the obtained threshold values was respectively assigned for a specific food product, 
as displayed in Fig. 3. 
 
The threshold values revealed low PDE5 inhibition within 4.0%–25.8% for all blank 
matrices of the food products, as expected from any non-adulterated sample, except 
for the blank ICP. The blank ICP produced an average of 91.0% PDE5 inhibition with 
a calculated threshold value of 94.3%. The selected blank matrix of the ICP was pre-
13 
 
determined by LC-HRMS analysis to be free from any PDE5 inhibitors and was 
expected to produce a low PDE5 inhibition. Here, the matrix components may play a 
significant role in the observed outcome. Given the ambiguities of the ICP sample 
matrix which could comprise of either caffeinated or decaffeinated coffee, a 
decaffeinated blank ICP was also tested, yielding a calculated threshold value of 
48.1% to be used to qualify adulterated ICP samples. 
 
3.3. Assay validation 
The concentrations of enzyme and substrate are fixed at 4 pg/µL and 100 nM, 
respectively, for each reaction, based on the manufacturer's recommendation. The 
specific activity of the human recombinant PDE5A1 enzyme is 3100 U/µg, where 1 U 
represents the amount of enzyme that converts a picomole of cGMP to GMP per min. 
The specific activity assay exhibited a linear relationship between the PDE5 enzyme 
concentration and its activity based on the detection of GMP using a malachite green 
reagent. The molecular weight and purity of the PDE5 enzyme were determined using 
4%–20% SDS-PAGE, visualised using Coomassie staining34. 
 
Apart from monitoring its biological and pharmacological relevance, the PDE5 
inhibition assay is validated to certify the robustness of the assay performance. The 
validation also served to ensure that all the reagents supplied are working as 
described by its manufacturer. Therefore, an established PDE5 inhibitor, i.e. sildenafil, 
was chosen, serving as a reference for the enzyme inhibition. Furthermore, sildenafil 





Fig. 4 displays the concentration-response plot of sildenafil using the PDE5 inhibition 
assay. The sigmoidal curve shows that sildenafil inhibits the PDE5 activity down to a 
minimum level where the response remained unchanged. The curve conformed to a 
classic symmetrical sigmoidal shape, as typically observed from any concentration-
response plot of an enzyme inhibitor38,39. The obtained data fitted well to the 
regression model in Eq. 5 with a coefficient of determination (R2) of 0.9915. Sildenafil 
inhibits the PDE5 enzyme with an IC50 of 4.2 nM. The IC50 value is the concentration 
of an inhibitor required to reduce the enzyme activity by 50%, typically attributed to the 
potency of an inhibitor40. The IC50 value of sildenafil obtained from the PDE5 inhibition 
assay is comparable to those reported from previous studies ranging from 3.5–6.6 
nM41-45.  
 
Nevertheless, the published IC50 values of sildenafil may vary significantly, depending 
on the source and purity of the PDE5 enzyme; the type and concentration of substrate; 
as well as the selected assay procedure40,46. The well-to-well precisions of sample 
analysis were also acceptable with %CV within 0.7%–12.6%. These findings served 
to validate the overall assay performance, including the recommended concentrations 
of the PDE5 enzyme and its substrate. The enzyme reaction scheme thus complies 
with the Michaelis-Menten kinetic model47. 
 
3.4. Analysis of PDE5 inhibitors in food products 
Altogether, the 55 distinct food samples were screened using the PDE5 inhibition 
assay and subsequently verified via the confirmatory LC-HRMS analysis. The primary 
goal of the enzyme inhibition assay is to rapidly discriminate adulterated from the non-
adulterated food products through the presence of PDE5 inhibitors. Tables 2 to 4 
15 
 
summarise the results of the PDE5 inhibition assay, including the confirmatory LC-
HRMS analysis. Collectively, 49 samples inhibited the PDE5 enzyme with percentage 
inhibition within 75.7%–105.5%, significantly above the threshold values, and were 
registered as potentially adulterated samples. In contrast, only six food samples were 
marked as non-adulterated with PDE5 inhibition ranged from -3.3% to 18.2%, notably 
below the threshold values. Altogether, 17 samples produced average PDE5 
inhibitions exceeding 100%, which may have been contributed by the high 
concentrations of PDE5 inhibitors in the sample solutions. In these circumstances, the 
enzyme may have reached a saturation point within the one hour incubation period 
where no more inhibitors could bind to the catalytic domain of the PDE5 enzyme47. As 
the PDE5 inhibition assay is based on a simple mix-incubate-read format, the need to 
monitor the enzymatic reaction progress over a length of time was eliminated, making 
the saturation point insignificant to the assay outcomes. 
 
The PDE5 inhibition assay results, however, were not in full agreement with the 
confirmatory LC-HRMS analysis, particularly those of the ICP samples in Table 2, 
which were reported previously26. The LC-HRMS analysis resulted in 41 positive 
samples, with nine distinct PDE5 inhibitors identified via targeted analysis, while 
another four inhibitors detected by suspected-target screening. Sildenafil again 
dominated the top list of PDE5 inhibitors found as adulterants in male sexual 
performance products, as previously mentioned in Section 3.3. It was identified as a 
sole adulterant in 5 samples and also found in combination with other PDE5 inhibitors 
in 14 samples. Its popularity is often linked to the accessibility and low cost of raw 




Other PDE5 inhibitors identified via the LC-HRMS targeted analysis included: tadalafil 
(16 samples); thiodimethylsildenafil and thiosildenafil (13 samples each); 
dimethylsildenafil (10 samples); desmethylcarbodenafil, propoxyphenyl-
thiodimethylsildenafil, and propoxyphenyl-thiohydroxyhomosildenafil (2 samples 
each); and vardenafil (1 sample). The LC-HRMS analysis additionally detected 
hydroxythiohomosildenafil (2 samples); and 3,5-dimethylpiperazinyl-
dithiodesmethylcarbodenafil, nortadalafil, and propoxyphenyl-dimethylsildenafil (1 
sample each) via the suspected-target screening. In addition to the one adulterant per 
sample composition, these adulterants were also found in combination with each 
other, where each adulterated sample contains as many as five distinct PDE5 
inhibitors. 
 
The confirmatory LC-HRMS analysis verified the findings of the PDE5 inhibition assay 
for all food products in Tables 3 and 4, concluded as true-positive (24 samples) and 
true-negative (6 samples), except for the ICP samples. The blank ICP had previously 
produced significant PDE5 inhibition during the establishment of the threshold value 
in Section 3.2. Coincidently, the decaffeinated blank ICP also moderately inhibits the 
PDE5 enzyme. Both of these blank ICPs were pre-determined by LC-HRMS analysis 
to be free from any PDE5 inhibitors. Matrix components of the ICPs may, therefore, 
play a significant role in inhibiting the PDE5 enzyme, which resulted in false-positive 
outcomes of 8 ICP samples. Zero false-negative results indicated an acceptable 






Coffee is well known to contain caffeine, a central nervous system stimulant, making 
it the most widely consumed psychoactive substance worldwide49,50. Caffeine 
possesses a chemical structure similar to those of the purine ring of cGMP and cyclic-
3’,5’-adenosine monophosphate (cAMP). The heterocyclic ring structure of caffeine is 
also comparable to those of the pyrazolopyrimidine-7-one ring of sildenafil and 
imidazotriazine-4-one ring of vardenafil. Due to the structural similarities, caffeine may 
be expected to exhibit the same inhibitory effects as the PDE5 inhibitors. In fact, 
caffeine is one of the earliest PDE inhibitors, discovered through the bronchodilating 
effects of coffee51. These initial findings suggest that caffeine may act as a non-
selective PDE inhibitor, demonstrated by its inhibitory effects on diverse PDE 
families52. 
 
The literature about the role of caffeine on selective inhibition of the PDE5 enzyme in 
human, however, remained scarce. Nonetheless, a couple of studies have 
demonstrated the up-regulation of cGMP by caffeine, through relaxation of the penile 
erectile tissue of rabbits53 and rats54. A recent study via computational approach had 
also predicted the PDE5 inhibition potential of caffeine55. Furthermore, data from the 
National Health and Nutrition Examination Survey from the United States' male 
respondents revealed a lower incidence of erectile dysfunction with increased caffeine 
consumptions56,57. All of these findings, although via limited evidence, suggest the 
existence of PDE5 inhibition by caffeine. 
 
Coffee is, therefore, not a suitable matrix for the PDE5 inhibition assay. Other 
naturally-occurring non-selective PDE inhibitors such as theophylline from tea and 
theobromine from cocoa9 may exhibit similar findings. Thus, these kinds of food 
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products should be analysed with caution or excluded altogether from the PDE5 
inhibition assay. It is also worth noting that the adulteration of food products with 
caffeine is currently on the rise36. Accordingly, producing definite evidence of food 




A PDE5 inhibition assay was optimised and validated for high-throughput screening of 
PDE5 inhibitors, found as adulterants in food products. The three-step assay protocol, 
recorded via FP measurements, relied on a simple mix-incubate-read format, that is 
automation-friendly. Data interpretation is straightforward, discriminating adulterated 
food samples based on their PDE5 inhibition above the pre-determined threshold 
value. Altogether, the 55 distinct food samples, preliminarily screened via the PDE5 
inhibition assay, registered 49 potentially adulterated samples, while the remaining six 
samples were marked as non-adulterated. The assay results were then verified using 
the LC-HRMS via targeted analysis and suspected-target screening. The confirmatory 
LC-HRMS analysis was in agreement with the PDE5 inhibition assay results for all 
food products except for the ICP samples. These findings indicated false-positive 
results from 8 ICP samples (out of 25 ICP samples in total, or 32%), possibly due to 
the PDE5 inhibition activity of caffeine present in the sample matrix. The established 
assay procedure is, therefore, not suitable for certain types of food products such as 
ICP and those with the presence of naturally-occurring PDE inhibitors. The PDE5 
inhibition assay nevertheless has shown promising potential to rapidly screen PDE5 
inhibitors as adulterants in other types of food products. A two-tier screening strategy 
via rapid and confirmatory tests would enhance performance and productivity, where 
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the adulterated samples from the PDE5 inhibition assay can be credibly marked as 
priority for confirmatory analysis. 
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Table 1: Schematic three-step protocol of the phosphodiesterase 5 (PDE5) inhibition 











- 12.5 µL 12.5 µL 12.5 µL 
PDE assay buffer 22.5 µL 10.0 µL - - 
PDE5 inhibitors/ 
samples 
- - - 2.5 µL 
10% DMSO in 
PDE assay buffer 
2.5 µL 2.5 µL 2.5 µL - 
PDE5 enzyme  
(10 pg/ µL) 
- - 10.0 µL 10.0 µL 
Step 1 
Pipette into each microtiter plate well 
↓ ↓ ↓ ↓ 
Total reagents in each microtiter plate well (25 µL) 
↓ 
Incubate at room temperature for an hour 
Step 2 
↓ 
Pipette 50.0 µL diluted binding agent into each microtiter plate 
well 
↓ 
Incubate at room temperature for 20 min with slow shaking 
Step 3 
↓ 
Measure the fluorescent polarisation 
(excitation at 470 ± 5 nm and emission 528 ± 20 nm) 
↓ 
Calculate the percentage of inhibition 
(Abbreviations: FAM-cGMP, fluorescein-labelled cyclic-3’,5’-guanosine 






Table 2: Phosphodiesterase 5 (PDE5) inhibition assay results and confirmatory liquid 
chromatography-high-resolution mass spectrometry (LC-HRMS) analysis26 of instant 








































































































































































































*LC-HRMS data published in Mohd Yusop et al.26 




















Table 3: Phosphodiesterase 5 (PDE5) inhibition assay results and confirmatory liquid 
chromatography-high-resolution mass spectrometry (LC-HRMS) analysis of powdered 




































































































































































































































Table 4: Phosphodiesterase 5 (PDE5) inhibition assay results and confirmatory liquid 
chromatography-high-resolution mass spectrometry (LC-HRMS) analysis of the blank 
(BL) food matrices comprising powdered drink mix (PDM), honey (HNY), jelly (JLY), 





































































































Fig. 1: The structure of (A) sildenafil; (B) phosphodiesterase 5 (PDE5) enzyme; and 




































































FAM-cGMP (substrate) FAM-GMP (product) FAM-GMP-bead complex 































Fig. 2: Phosphodiesterase 5 (PDE5) inhibition assay scheme using fluorescence polarisation (FP) technique. (adapted and modified 
from BPS Bioscience Inc.24) (Abbreviations: FAM-cGMP, fluorescein-labelled cyclic-3’,5’-guanosine monophosphate; FAM-GMP, 
fluorescein-labelled 5’-guanosine monophosphate) [Colour figure can be viewed at wileyonlinelibrary.com]
1-hour incubation 20-min incubation 
PDE5 enzyme activity 
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Fig. 3: Threshold values for each blank matrices of the food product. 






















































































































IC50 = 4.2 nM
 
 
Fig. 4: The concentration-response plot of sildenafil. (Abbreviations: PDE5, 
phosphodiesterase 5; R2, coefficient of determination; IC50, half-maximal inhibitory 
concentration; Log10, logarithm with base 10) 
 
 
 
